Patients with colorectal liver metastases gain wider access to unique benefits of yttrium-90 internal radiation therapy in the Netherlands

London, UK, 05 April 2016

Selective internal radiation therapy (SIRT), including TheraSphere®, reimbursed by Zorginstituut Nederland

BTG plc (LSE: BTG), a global specialist healthcare company is pleased to announce that, following a decision by the Netherlands Healthcare Institute, Selective Internal Radiation Therapy (SIRT) will be reimbursed by Zorginstituut Nederland (ZIN), for patients with colorectal liver metastases (mCRC) who have failed or are intolerant to chemotherapy. The decision to reimburse SIRT, which includes TheraSphere® yttrium-90 glass microsphere therapy, will provide physicians with greater flexibility in treatment strategy enabling them to utilise the benefits of treatments such as TheraSphere® and maximise patient outcomes as a result.
 
Professor Marnix Lam, Nuclear Medicine Physician at University Medical Center Utrecht, Netherlands, said “Reimbursement of yttrium-90 radioembolisation for colorectal cancer patients in the Netherlands is a breakthrough for patients and recognition of minimally invasive image-guided treatment as an important treatment modality in oncology.”
 
“We are delighted that a larger population of mCRC patients in the Netherlands will now have greater access to SIRT,” commented Jim Matons, BTG VP Commercial Operations, EMEA. “Reimbursing yttrium-90 SIRT, such as TheraSphere®, which can be delivered at a specific radiation dose based on an individual patient’s need, represents a significant step forward in treatment of mCRC, with the potential to lead to better patient outcomes.
 
-ENDS-

About BTG Interventional Medicine

 
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: www.btg-im.com.
 
About TheraSphere®
 
TheraSphere® 90Y glass microspheres are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy, delivering high doses of radiation to liver tumors while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.
 
In the EU, TheraSphere® is CE Marked for the treatment of hepatic neoplasia. In the US, TheraSphere® is FDA approved under a Humanitarian Device Exemption (HDE) for the treatment of hepatocellular carcinoma (HCC).


For full instructions for use and important safety information, please visit www.therasphere.com.
 
For further information contact:
 
BTG plc
Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178
 
Media Liaison
Jonathan Kearney
+44 208 618 2755; Mobile: +44 7725 925 841